期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 43, 期 5, 页码 378-391出版社
CELL PRESS
DOI: 10.1016/j.tips.2022.02.005
关键词
-
资金
- National Institutes of Health [R01-CA-208335-01-A1]
- Rogel Scholar award
The mutational and phenotypic landscape of tumors is dynamic, and constant monitoring of cancer patients using liquid biopsy can provide important tumor information for diagnosis, prognosis, and treatment.
The mutational and phenotypic landscape of tumors is dynamic, requiring constant monitoring of cancer patients to provide the most up-to-date and effective care. Circulating tumor cells (CTCs) obtained via liquid biopsy can provide tumor DNA, RNA, and protein information that can aid in the diagnosis, prognosis, and treatment of patients. There have been many recent studies and advances in using CTC enumeration, characterization, and expansion to provide personalized cancer treatment, validating the benefit of using CTCs as a biomarker in standard of care procedures. In this paper, we aim to summarize these advances, their limitations, and suggest future areas of study necessary to bring CTC analysis to clinics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据